9 pending office actions • 4 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Merck Patent GmbH | 6 |
| Merck Patent GmbH | 1 |
| Pfizer, Inc. | 1 |
| Ryvu Therapeutics S.A. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18291529 | SRPK INHIBITORS | Merck Patent GmbH | MOTEVALLI, OROD | 1628 | Non-Final OA | Jan 23, 2024 |
| 18414253 | INFECTED CELL CULTURES | Merck Patent GmbH | MCNEIL, STEPHANIE A N | 1653 | Final Rejection | Jan 16, 2024 |
| 18564968 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH | MCKOY, QUINCY ANDRE | 1626 | Non-Final OA | Nov 28, 2023 |
| 18313652 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | Merck Patent GmbH | WILLIS, DOUGLAS M | 1624 | Non-Final OA | May 08, 2023 |
| 18033813 | PROTEINS FOR THE DETECTION OF SCHISTOSOMA INFECTION | Merck Patent GmbH | CHEONG, CHEOM-GIL | 1645 | Non-Final OA | Apr 26, 2023 |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | Pfizer, Inc. | JOHANSEN, PETER N. | 1644 | Final Rejection | Dec 23, 2022 |
| 17906617 | AMIDE DERIVATIVES | Ryvu Therapeutics S.A. | WILLIS, DOUGLAS M | 1624 | Final Rejection | Sep 17, 2022 |
| 17783704 | USE OF THE GDF-5 MUTANT FOR THE TREATMENT OF PAIN AND CARTILAGE DESTRUCTION | Merck Patent GmbH | MARTINEZ, TARA L | 1654 | Final Rejection | Jun 09, 2022 |
| 17774685 | Anti-TIGIT Antibodies and Uses Thereof | Merck Patent GmbH | SANG, HONG | 1646 | Non-Final OA | May 05, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial